Page last updated: 2024-10-21

pd 173074 and Brain Neoplasms

pd 173074 has been researched along with Brain Neoplasms in 5 studies

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research Excerpts

ExcerptRelevanceReference
"The effects of the FGFR inhibitor PD173074, the FAK inhibitors PF431396 and Y15 and the αvβ3/αvβ5 integrin inhibitor cilengitide were assessed in L1-positive and L1-negative variants of the human glioblastoma-derived cell lines T98G and U-118 MG."3.83Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation. ( Anderson, HJ; Galileo, DS, 2016)
"Inhibition of FGFR kinase corrects the aneuploidy, and oral administration of an FGFR inhibitor prolongs survival of mice harboring intracranial FGFR3-TACC3-initiated glioma."1.38Transforming fusions of FGFR and TACC genes in human glioblastoma. ( Aldape, K; Brat, DJ; Castano, A; Ceccarelli, M; Chan, JM; Finocchiaro, G; Gao, Z; Golfinos, JG; Guha, A; Iavarone, A; Lasorella, A; Liu, EM; Mikkelsen, T; Niola, F; Pellegatta, S; Porrati, P; Qiu, K; Rabadan, R; Reichel, J; Riccardi, R; Singh, D; Sullivan, R; Zagzag, D; Zoppoli, P, 2012)
"To validate this model in primary human pituitary tumors, we examined the expression of ptd-FGFR4, N-cadherin, and clinical behavior."1.33Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications. ( Asa, SL; Ezzat, S; Winer, D; Zheng, L, 2006)

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ma, J1
Benitez, JA1
Li, J1
Miki, S1
Ponte de Albuquerque, C1
Galatro, T1
Orellana, L1
Zanca, C1
Reed, R1
Boyer, A1
Koga, T1
Varki, NM1
Fenton, TR1
Nagahashi Marie, SK1
Lindahl, E1
Gahman, TC1
Shiau, AK1
Zhou, H1
DeGroot, J1
Sulman, EP1
Cavenee, WK1
Kolodner, RD1
Chen, CC1
Furnari, FB1
Anderson, HJ1
Galileo, DS2
Singh, D1
Chan, JM1
Zoppoli, P1
Niola, F1
Sullivan, R1
Castano, A1
Liu, EM1
Reichel, J1
Porrati, P1
Pellegatta, S1
Qiu, K1
Gao, Z1
Ceccarelli, M1
Riccardi, R1
Brat, DJ1
Guha, A1
Aldape, K1
Golfinos, JG1
Zagzag, D1
Mikkelsen, T1
Finocchiaro, G1
Lasorella, A1
Rabadan, R1
Iavarone, A1
Mohanan, V1
Temburni, MK1
Kappes, JC1
Ezzat, S1
Zheng, L1
Winer, D1
Asa, SL1

Other Studies

5 other studies available for pd 173074 and Brain Neoplasms

ArticleYear
Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair.
    Cancer cell, 2019, 03-18, Volume: 35, Issue:3

    Topics: Animals; Brain Neoplasms; Cell Nucleus; DNA Repair; Female; Glioma; Humans; Male; Mice; Phosphorylat

2019
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
    Cellular oncology (Dordrecht), 2016, Volume: 39, Issue:3

    Topics: Aniline Compounds; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Pro

2016
Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Science (New York, N.Y.), 2012, Sep-07, Volume: 337, Issue:6099

    Topics: Aneuploidy; Animals; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Transformation, Neopla

2012
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
    Clinical & experimental metastasis, 2013, Volume: 30, Issue:4

    Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Apoptosis; Blotting, Western; B

2013
Targeting N-cadherin through fibroblast growth factor receptor-4: distinct pathogenetic and therapeutic implications.
    Molecular endocrinology (Baltimore, Md.), 2006, Volume: 20, Issue:11

    Topics: Adenoma; Animals; Antineoplastic Agents; Brain Neoplasms; Cadherins; Cell Proliferation; Cells, Cult

2006